Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Chemicals & Drugs
>
Amino Acid
>
Actinomycin D1
Actinomycin D1
Actinomycin D1 is a potent antitumor antibiotic produced by Streptomyces bacteria.
It functions as a DNA-binding agent, inhibiting RNA synthesis and cell division.
Actinomycin D1 has been utilized in the treatment of various cancers, including Wilms' tumor, testicular carcinoma, and Ewing's sarcoma.
Researchers can optimize their Actinomycin D1 studies using PubCompare.ai's AI-driven insights to locate the best protocols from literature, preprints, and patents, with intelligent comparisons to identify the optimal products and procedures.
This streamlines the research workflow and elevates Actinomycin D1 studies with PubCompare.ai's intuitive platform.
It functions as a DNA-binding agent, inhibiting RNA synthesis and cell division.
Actinomycin D1 has been utilized in the treatment of various cancers, including Wilms' tumor, testicular carcinoma, and Ewing's sarcoma.
Researchers can optimize their Actinomycin D1 studies using PubCompare.ai's AI-driven insights to locate the best protocols from literature, preprints, and patents, with intelligent comparisons to identify the optimal products and procedures.
This streamlines the research workflow and elevates Actinomycin D1 studies with PubCompare.ai's intuitive platform.
Most cited protocols related to «Actinomycin D1»
Actins
Biotin
Buffers
Cells
Chloroform
Dactinomycin
Dimethylformamide
Edetic Acid
Glycogen
HEPES
isolation
Isopropyl Alcohol
N-biotinylaminoethyl methanethiosulfonate
Oligonucleotide Primers
prisma
RNA, Viral
RNA Decay
Sodium Chloride
Streptavidin
Transcription, Genetic
trizol
Tromethamine
Tween 20
Cells
Dactinomycin
RNA, Messenger
CCND1 protein, human
Dactinomycin
DNA, Complementary
GAPDH protein, human
Genes
Interleukin-1 beta
Oligonucleotide Primers
Proliferating Cell Nuclear Antigen
PTGS2 protein, human
RNA, Messenger
Transcription, Genetic
Total RNA extracted from cancer cell lines and breast cancer and normal tissue samples were subjected to qRT-PCR and Western blot analysis. Cancer cell lines were transfected with scrambled-siRNA or METTL14-siRNA/ALKBH5-siRNA (Sigma-Aldrich) for 48 or 72 hours before they were subjected to qRT-PCR or Western blot analysis, as described previously (42 (link)). Primers used in this study are mentioned in table S1. Antibodies against ALKBH5 (#HPA 007196), β-actin (#A3854), GAPDH (#G9295), and METTL14 (#HPA038002) were purchased from Sigma-Aldrich. Antibodies against TGFβ1 (#ab155264), m6A (#ab151230), and YTHDF3 (#ab103328) were purchased from Abcam Inc. Antibodies against cyclin D1 (#2978), CDK4 (#12790), PARP (#5625S), SMAD3 (#9513), P27/KIP1 (#2552s), and pSMAD3 (#9520) were purchased from Cell Signaling Technology. The antibodies against cyclin E1 (#SC-4976), HuR (3A2) (#SC-5261), and pSMAD3 (#SC-11769) were purchased from Santa Cruz Biotechnology. The antibody against HMGA2 (GTX629478) was purchased from GeneTex. Actinomycin D (catalog no. A1410) was purchased from Sigma-Aldrich.
Actins
Antibodies
CCNE1 protein, human
CDKN1B protein, human
Cell Lines
Cyclin D1
Dactinomycin
GAPDH protein, human
HMGA2 protein, human
Immunoglobulins
Malignant Neoplasm of Breast
Malignant Neoplasms
METTL14 protein, human
Oligonucleotide Primers
RNA, Small Interfering
SMAD3 protein, human
TGF-beta1
Tissues
Western Blot
HeLa cells (HeLa CCL-2) and HeLa-C cells (the gift of Volker Cordes, Max Planck Institute, Goettingen, Germany) were cultured in high-glucose DMEM (Cellgro, Manassas, VA) supplemented with 10% FBS as described previously (Griffis et al., 2002 (link)). Transient transfection was performed using either Fugene 6 (Roche Diagnostics, Indianapolis, IN) or Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Unless otherwise indicated, transcriptions typically used 0.2–0.5 μg of DNA per well of a six-well plate. For transcriptional inhibition, cells were treated for 4 h with 5 μg/ml actinomycin D1 (Roche).
To enrich for mitotic cells, HeLa cells transfected with various GFP-fusions using Lipofectamine 2000 were synchronized by thymidine/nocodazole block (Zhu and Jiang, 2005 (link)). Twenty hours after transfection, cells were blocked in S phase with 2 mM thymidine for 16 h. After release into fresh medium for 6 h, cells were blocked in M phase with 20 ng/ml nocodazole for 12 h. Mitotic cells were collected by shake-off, pelleted and washed with PBS, suspended in fresh medium, and transferred to wells containing poly-l -lysine–coated glass coverslips. Coverslips were collected and fixed for immunofluorescence every 20 min up to 1 h after release.
For immunofluorescence assays, cells were plated on coverslips in six-well plates. Fourteen to eighteen hours after transfection, cells were washed with PBS, fixed 10 min at RT with 4% formaldehyde (methanol-free; Polysciences, Warrington, PA) in PBS, permeabilized with 0.2% Triton X-100, and processed as described previously (Griffis et al., 2002 (link)). The following antibodies were used in these experiments: anti-Nup98 (1:2000; Griffis et al., 2002 (link)), monoclonal 414 (1:1000; Calbiochem, La Jolla, CA), CREST serum (1:250; Antibodies Incorporated, Davis, CA), and chicken anti-mouse Gle2 (1:200). Antibodies were detected using Alexa Fluor–conjugated secondary antibodies with the exception of chicken anti-Gle2, which was detected using rhodamine-conjugated donkey anti-chicken (1:500). For staining with CenpA antibody (1:400, Cell Signaling Technology, Danvers, MA), cells were fixed for 10 min at −20°C with 100% methanol.
Epifluorescence images were captured using a BX-60 microscope (Olympus, Tokyo, Japan) equipped with an eight-bit camera (Dage-MTI, Michigan City, IN) and IP Lab software (Scanalytics, Fairfax, VA). When indicated, TIFF files were deconvolved using Simple PCI software (Compix, Cranberry Township, PA) and a nearest-neighbor algorithm. For simultaneous detection of CFP and YFP, or CFP and GFP fusion proteins, a Zeiss LSM510 Meta-equipped confocal microscope was used (Carl Zeiss, Thornwood, NY). To simultaneously image CFP and YFP, excitation of CFP was at 458 nm, with emission monitored at 463–495 nm. YFP was excited at 514 nm, and emission monitored at 516–570 nm. For simultaneous imaging of CFP and GFP, excitation was at 458 nm, emission was monitored at 463–612 nm, and Zeiss online fingerprinting software was used to separate CFP and GFP images. The images inFigure 6 B were taken from a z-stack captured using a three-dimensional microscopy system (Intelligent Imaging Innovations, Denver, CO) based on a 200M microscope (Zeiss) equipped with a 12-bit Cool Snap HQ camera (Photometrics, Tucson, AZ) and Slidebook software (Intelligent Imaging Innovations). Deconvolution (nearest neighbors algorithm) and surface rendering were performed using Slidebook.
To enrich for mitotic cells, HeLa cells transfected with various GFP-fusions using Lipofectamine 2000 were synchronized by thymidine/nocodazole block (Zhu and Jiang, 2005 (link)). Twenty hours after transfection, cells were blocked in S phase with 2 mM thymidine for 16 h. After release into fresh medium for 6 h, cells were blocked in M phase with 20 ng/ml nocodazole for 12 h. Mitotic cells were collected by shake-off, pelleted and washed with PBS, suspended in fresh medium, and transferred to wells containing poly-
For immunofluorescence assays, cells were plated on coverslips in six-well plates. Fourteen to eighteen hours after transfection, cells were washed with PBS, fixed 10 min at RT with 4% formaldehyde (methanol-free; Polysciences, Warrington, PA) in PBS, permeabilized with 0.2% Triton X-100, and processed as described previously (Griffis et al., 2002 (link)). The following antibodies were used in these experiments: anti-Nup98 (1:2000; Griffis et al., 2002 (link)), monoclonal 414 (1:1000; Calbiochem, La Jolla, CA), CREST serum (1:250; Antibodies Incorporated, Davis, CA), and chicken anti-mouse Gle2 (1:200). Antibodies were detected using Alexa Fluor–conjugated secondary antibodies with the exception of chicken anti-Gle2, which was detected using rhodamine-conjugated donkey anti-chicken (1:500). For staining with CenpA antibody (1:400, Cell Signaling Technology, Danvers, MA), cells were fixed for 10 min at −20°C with 100% methanol.
Epifluorescence images were captured using a BX-60 microscope (Olympus, Tokyo, Japan) equipped with an eight-bit camera (Dage-MTI, Michigan City, IN) and IP Lab software (Scanalytics, Fairfax, VA). When indicated, TIFF files were deconvolved using Simple PCI software (Compix, Cranberry Township, PA) and a nearest-neighbor algorithm. For simultaneous detection of CFP and YFP, or CFP and GFP fusion proteins, a Zeiss LSM510 Meta-equipped confocal microscope was used (Carl Zeiss, Thornwood, NY). To simultaneously image CFP and YFP, excitation of CFP was at 458 nm, with emission monitored at 463–495 nm. YFP was excited at 514 nm, and emission monitored at 516–570 nm. For simultaneous imaging of CFP and GFP, excitation was at 458 nm, emission was monitored at 463–612 nm, and Zeiss online fingerprinting software was used to separate CFP and GFP images. The images in
actinomycin D1
Anti-Antibodies
Antibodies
Cells
Chickens
Cranberry
Crista Ampullaris
Diagnosis
Division Phase, Cell
Equus asinus
Fluorescent Antibody Technique, Direct
Formaldehyde
FuGene
Glucose
HeLa Cells
Immunofluorescence
Immunoglobulins
Innovativeness
lipofectamine 2000
Lysine
Methanol
Microscopy
Microscopy, Confocal
Mus
Nocodazole
Nup98 protein, human
Poly A
Proteins
Psychological Inhibition
Rhodamine
Serum
Thymidine
Transcription, Genetic
Transfection
Transients
Tremor
Triton X-100
Most recents protocols related to «Actinomycin D1»
The shPRMT6 plasmid and control plasmid were purchased from GeneChem (Shanghai, China). PRMT6 overexpression plasmid and empty vector were obtained from Tsingke (Beijing, China). shYTHDF2 and shCDK9 plasmids, along with their respective control plasmids, and YTHDF2 and CDK9 overexpression plasmids, were also sourced from Tsingke (Beijing, China). YTHDF2 promoter-driven luciferase reporter gene plasmid and Renilla luciferase control plasmid were acquired from OBiO Technology (Shanghai, China). EPZ020411 was purchased from Cayman (USA), CHIR-99,021 (Cat#HY-10,182 A) and Actinomycin D (Cat#HY-17,559) were from MCE (USA). The anti-PRMT6 (Cat#14,641) antibody was from CST (Boston, MA, USA). Antibodies against YTHDF2 (Cat#24744-1-AP), Cyclin D1 (Cat#60186-1-Ig), E-cadherin (Cat#20874-1-AP), and N-cadherin (Cat#22018-1-AP) were from Proteintech (Wuhan, China). Anti-β-catenin (Cat#PK02151), Vimentin (Cat#T55134) antibodies were from Abmart (Shanghai, China). Anti-p-β-catenin (Cat#sc-57,535), GSK-3β (Cat#sc-53,931) antibodies were from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-APC (Cat#WL02422), c-Myc (Cat#WL01781) antibodies were from Wanleibio (Shenyang, China). Anti-Histone H3R2me2a antibodies were from Genetex (USA, Cat#GTX54134) and PTM BIO (Hangzhou, China, Cat#PTM668). Anti-CDK9 antibodies were from Abcam (UK, Cat#ab239364) and Santa Cruz Biotechnology (USA, Cat#sc-13130x).
Full text: Click here
The shPRMT6 plasmid and control plasmid were purchased from GeneChem (Shanghai, China). PRMT6 overexpression plasmid and empty vector were obtained from Tsingke (Beijing, China). shYTHDF2 and shCDK9 plasmids, along with their respective control plasmids, and YTHDF2 and CDK9 overexpression plasmids, were also sourced from Tsingke (Beijing, China). YTHDF2 promoter-driven luciferase reporter gene plasmid and Renilla luciferase control plasmid were acquired from OBiO Technology (Shanghai, China). EPZ020411 was purchased from Cayman (USA), CHIR-99021 (Cat#HY-10182A) and Actinomycin D (Cat#HY-17559) were from MCE (USA). The anti-PRMT6 (Cat#14641) antibody was from CST (Boston, MA, USA). Antibodies against YTHDF2 (Cat#24744-1-AP), Cyclin D1 (Cat#60186-1-Ig), E-cadherin (Cat#20874-1-AP), and N-cadherin (Cat#22018-1-AP) were from Proteintech (Wuhan, China). Anti-βcatenin (Cat#PK02151), Vimentin (Cat#T55134) antibodies were from Abmart (Shanghai, China). Anti-pβ-catenin (Cat#sc-57535), GSK-3β (Cat#sc-53931) antibodies were from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-APC (Cat#WL02422), c-Myc (Cat#WL01781) antibodies were from Wanleibio (Shenyang, China). Anti-Histone H3R2me2a antibodies were from Genetex (USA, Cat#GTX54134) and PTM BIO (Hangzhou, China, Cat#PTM668). Anti-CDK9 antibodies were from Abcam (UK, Cat#ab239364) and Santa Cruz Biotechnology (USA, Cat#sc-13130x).
To detect the cyclin D1 mRNA stability, the ASMCs were treated with actinomycin (Act D, 2 µg/mL) treatment for 0, 3 and 6 h. The relative remaining RNA level was detected by qRT-PCR and the half-life of cyclin D1 mRNA was examined by transcript levels at indicated time points relative to those before Act D treatment.
Full text: Click here
Actinomycin
CCND1 protein, human
Dactinomycin
RNA, Messenger
Mouse bone marrow cells were differentiated into macrophages in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) low-endotoxin fetal bovine serum (FBS; Omega Scientific) and 20% (v/v) L929-conditioned medium for 5 days. For stimulation, cells were replated overnight at 1.0 × 105 cells per well in 96-well plates. For inflammasome stimulations, cells were primed with Pam3CSK4 (1 μg ml−1) for 5 h and then stimulated with 10 μg ml−1 nigericin in Opti-MEM I media (Thermo Fisher Scientific). For flagellin or LPS electroporation39 (link), 1.0 × 106 Pam3CSK4-primed BMDMs were electroporated with 1.0 μg LPS or 0.2 μg flagellin in 100 μl R buffer using a neon 100-μl tip with 1,720 voltage, 10 width, 2 pulse settings. Electroporated cells were added to 990 μl Opti-MEM I medium and cultured for 2 h. BMDMs treated with venetoclax (25 μM for 6 h), doxorubicin (10 μM for 6 h), TNF plus actinomycin D (20 ng ml−1 TNF, 500 ng ml−1 actinomycin D for 6 h), or TNF plus zVAD (100 ng ml−1 TNF, 20 μM zVAD for 16 h) were not primed. For lysis controls, cells were lysed with 0.25% Triton-X100 in medium. Where indicated, BMDMs were cultured with the indicated concentration of anti-NINJ1 clone 251 (link) (mouse IgG2a; Genentech), anti-NINJ1 clone D1 (mouse IgG2a; Genentech), anti-ninjurin clone 50 (BD Biosciences BD610777, raised against human NINJ1), or an isotype control mouse IgG2a (Thermo Fisher Scientific). Prior to addition to cells, anti-ninjurin clone 50 and isotype control mouse IgG2a antibodies were dialysed against PBS to remove sodium azide using Slide-A-Lyzer MINI Dialysis Device with a 10K MWCO (Thermo Fisher Scientific) according to the manufacturer’s instructions. Synthetic peptides used were mouse NINJ1 amino acids 26–37 (PPRWGLRNRPIN, Genentech) and its sequence-scrambled analogue (PWPPRRNRNGLI, Genentech). BMDMs were pre-treated with antibody or peptide for 10 min prior to addition of treatment.
Full text: Click here
actinomycin D1
Amino Acids
Antibodies
Bone Marrow Cells
Buffers
Cells
Clone Cells
Culture Media, Conditioned
Dactinomycin
Dialysis
Doxorubicin
Eagle
Endotoxins
Flagellin
Homo sapiens
IgG2A
Immunoglobulin Isotypes
Immunoglobulins
Inflammasomes
Macrophage
Medical Devices
Mus
Neon
Nigericin
Peptides
Pulse Rate
Sodium Azide
Triton X-100
venetoclax
Example 79
1. Hemophilia
A patient suffering from hemophilia A is diagnosed. A composition of exogenous FVIII expressing enucleated hematopoietic cells is prepared as described herein. 10{circumflex over ( )}9 of the cells are administered intravenously to the patient. The clotting rate is assessed with a standard in vitro clotting time assay known in the art. Circulating antibodies against FVIII are detected in serum as described herein. The levels of circulating antibodies are assessed to track the effectiveness of immune tolerance induction. If the clotting cascade activity is insufficient to ensure healthy coagulation, recombinant or isolated FVIII are administered concurrently intravenously in order to reduce the symptoms of hemophilia A.
2. Atypical Hemolytic Uremic Syndrome
A patient suffering from atypical hemolytic uremic syndrome (aHUS) is diagnosed. A composition of exogenous CFH expressing enucleated hematopoietic cells is prepared as described herein. 10{circumflex over ( )}9 of the cells are administered intravenously to the patient. The symptomatic hemolysis rate is assessed with a standard urinary hemolysis assay known in the art. Circulating antibodies against CFH are detected in serum as described herein. The levels of circulating antibodies are assessed to track the effectiveness of immune tolerance induction. The patient is administered the treatment until the symptoms of the disease are seen to ameliorate using the assays described herein.
3. Multiple Sclerosis
An individual with multiple sclerosis (MS) receives a single infusion of 1×10{circumflex over ( )}9 antigen expressing enucleated hematopoietic cells expressing the antigenic polypeptide myelin basic protein (MBP), produced and formulated as described herein. At the day of study drug administration, the patient is monitored in a phase 1 inpatient unit for 24 hours. Measurement of the primary outcome is performed at month 3 and additional safety follow-up is performed until month 6 with consecutive clinical, MRI, and general physical examinations as well as clinical and laboratory analyses to assess adverse events and monitor MS disease activity. The procedure is repeated until tolerance is induced such that the symptoms of MS are ameliorated in the individual. See, for example, Andreas Lutterotti et al. Sci Transl Med 5, 188ra75 (2013).
Frequency of different cell subsets is analyzed in whole blood (EDTA tubes) by flow cytometry with the following antibody panels: for immune cell subsets (granulocytes, eosinophils, monocytes, and B, T, NK, and NK T cells)—anti-CD45 (PE-Cy7, eBioscience), anti-CD16, (APC-Cy7, BioLegend), anti-CD19 [fluorescein isothiocyanate (FITC), BD], anti-CD14 (V450, BD), anti-CD3 [peridinin chlorophyll protein (PerCP), BD], and anti-CD56 [phycoerythrin (PE), eBioscience]; for T cell subsets including CD4+, FoxP3+ Tregs, regulatory CD8+CD57+ILT2+, and proinflammatory CD8+CD161high T cells-anti-CD3 (PE-Cy7, eBioscience), anti-CD4 (APC, eBioscience), anti-CD8 [Pacific Blue (PB), Dako-Biozol], anti-FoxP3 (PE, Miltenyi), anti-CD25 (APC, eBioscience), anti-CD57 (FITC, BD), anti-ILT2 (PE, Beckman), and anti-CD161 (APC, Miltenyi). The corresponding isotype controls are included in all stainings. Cells are analyzed with an LSR-II flow cytometer (BD) and FACSDiva Software (BD).
Peripheral blood mononuclear cells (PBMCs) are isolated by Ficoll density gradient centrifugation (PAA), and functional phenotype of T cells is evaluated by intracellular cytokine staining as follows: 5×10{circumflex over ( )}5 freshly isolated PBMCs are incubated overnight in 200 ml of X-VIVO 15 (Lonza) in a sterile FACS tube. The next day, cells are stimulated with phorbol 12-myristate 13-acetate (50 ng/ml, Sigma) and ionomycin (1 mg/ml, Sigma) in the presence of brefeldin A (10 mg/ml, eBioscience) for 5 hours. After washing with phosphate-buffered saline, cells are stained with LiveDead kit (AmCyan, Invitrogen), fixed, permeabilized, and stained with different antibodies: anti-IL-17 (Alexa Fluor 647; eBioscience), anti-IL-4 (PE-Cy7, BioLegend), anti-IFN-g (FITC, BioLegend), anti-IL-10 (PE; BioLegend), anti-CD3 (PE, DakoCytomation), anti-CD4 (PB, DakoCytomation), and anti-CD8 (PB, BioLegend) or with the corresponding isotype controls.
The antigen-specific T cell responses toward the myelin peptide used in the study are measured in freshly isolated PBMCs before the tolerization procedure and after 3 months. Antigen-specific T cell responses are analyzed by proliferation assays with thymidine incorporation. Briefly, isolated PBMCs are seeded in 96-well plates at 1.5×10{circumflex over ( )}5 PBMCs per well in X-VIVO 15 medium (Lonza) with 1 mM of peptide. Forty-eight wells are seeded per antigen, and six wells only with medium as negative control in each plate. TTx (5 mg/ml) (Novartis Behring) is used as positive control. On day 7, plates are incubated for 15 hours with 1 mCi of [3H] thymidine (Hartmann Analytic). [3H] thymidine-pulsed plates are analyzed with a scintillation b counter (Wallac 1450, PerkinElmer). The scintillation counts (CPM) of each well are measured. Wells showing CPM higher than the mean+3 SDs of the unstimulated wells are considered as positive.
Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which these inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the inventions are not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Tables A-J
Full text: Click here
Top products related to «Actinomycin D1»
Sourced in United States, Germany, United Kingdom, China, Macao, Japan, Sao Tome and Principe, France, Senegal
Actinomycin D is a laboratory-grade chemical compound used in various research applications. It is a polypeptide antibiotic produced by the bacterium Streptomyces parvullus. Actinomycin D is known for its ability to inhibit DNA-dependent RNA synthesis, making it a valuable tool for researchers studying cellular processes and gene expression.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
Sourced in Japan, United States, Germany
MG132 is a proteasome inhibitor. It functions by blocking the 26S proteasome, a key component of the cellular protein degradation system.
Sourced in United States, United Kingdom
P27Kip1 is a cell cycle regulatory protein that inhibits the activity of cyclin-dependent kinases (CDKs), thereby arresting the cell cycle progression. It plays a crucial role in the regulation of cell proliferation and differentiation.
Sourced in United States, United Kingdom, Germany, China, Canada, Italy, Japan, Morocco, Israel, Australia, France, Sao Tome and Principe, Denmark
GAPDH is an enzyme that catalyzes the sixth step of glycolysis, the metabolic pathway that converts glucose into energy. It is responsible for the conversion of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate. GAPDH is commonly used as a control or reference gene in molecular biology experiments.
Sourced in United States
Mouse anti-cyclin D3 is a primary antibody that recognizes the cyclin D3 protein. Cyclin D3 is a regulatory subunit of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), which are involved in cell cycle progression.
Sourced in United States, Germany
Calyculin A is a protein phosphatase inhibitor isolated from the marine sponge Halichondria okadai. It is primarily used in research applications as a tool compound to study cellular signaling pathways involving protein phosphatases.
Rabbit anti-53BP1 (4937) is a primary antibody that specifically recognizes the 53BP1 protein. 53BP1 is a key regulator of the DNA damage response pathway.
Sourced in United States
The SpectraMax L luminometer is a versatile laboratory instrument designed for sensitive luminescence detection. It measures the light emitted from bioluminescent or chemiluminescent reactions, providing accurate and reliable data for a wide range of applications.
Sourced in United States
Mimosine is a chemical compound used in various laboratory applications. It is a non-protein amino acid derived from the Mimosa pudica plant. Mimosine is commonly utilized in research settings for its biochemical properties, but a detailed description of its core function is not available while maintaining an unbiased and factual approach.
More about "Actinomycin D1"
Actinomycin D1, also known as dactinomycin, is a potent antitumor antibiotic produced by Streptomyces bacteria.
It functions as a DNA-binding agent, inhibiting RNA synthesis and cell division.
Actinomycin D1 has been utilized in the treatment of various cancers, including Wilms' tumor, testicular carcinoma, and Ewing's sarcoma.
Researchers can optimize their Actinomycin D1 studies using PubCompare.ai's AI-driven insights to locate the best protocols from literature, preprints, and patents, with intelligent comparisons to identify the optimal products and procedures.
This streamlines the research workflow and elevates Actinomycin D1 studies with PubCompare.ai's intuitive platform.
Actinomycin D, a closely related compound, is also a DNA-binding agent that inhibits RNA synthesis.
Penicillin/streptomycin is a common antibiotic mixture used in cell culture to prevent bacterial contamination.
MG132 is a proteasome inhibitor used to study protein degradation, while p27Kip1 is a cyclin-dependent kinase inhibitor involved in cell cycle regulation.
GAPDH is a commonly used housekeeping gene for normalizing gene expression data, and Mouse anti-cyclin D3 is a specific antibody used to detect this cell cycle regulator.
Calyculin A is a protein phosphatase inhibitor, and Rabbit anti-53BP1 (4937) is an antibody that recognizes the DNA damage response protein 53BP1.
The SpectraMax L luminometer is a device used for quantifying luminescent signals, such as those generated by luciferase reporter assays.
Mimosine is an amino acid that can induce cell cycle arrest at the G1/S transition.
By incorporating these related terms and concepts, researchers can enhance their understanding and optimization of Actinomycin D1 studies, leveraging the power of PubCompare.ai's AI-driven insights to streamline their research workflow and achieve better results.
One typo: 'Actnomycin D1' should be 'Actinomycin D1'.
It functions as a DNA-binding agent, inhibiting RNA synthesis and cell division.
Actinomycin D1 has been utilized in the treatment of various cancers, including Wilms' tumor, testicular carcinoma, and Ewing's sarcoma.
Researchers can optimize their Actinomycin D1 studies using PubCompare.ai's AI-driven insights to locate the best protocols from literature, preprints, and patents, with intelligent comparisons to identify the optimal products and procedures.
This streamlines the research workflow and elevates Actinomycin D1 studies with PubCompare.ai's intuitive platform.
Actinomycin D, a closely related compound, is also a DNA-binding agent that inhibits RNA synthesis.
Penicillin/streptomycin is a common antibiotic mixture used in cell culture to prevent bacterial contamination.
MG132 is a proteasome inhibitor used to study protein degradation, while p27Kip1 is a cyclin-dependent kinase inhibitor involved in cell cycle regulation.
GAPDH is a commonly used housekeeping gene for normalizing gene expression data, and Mouse anti-cyclin D3 is a specific antibody used to detect this cell cycle regulator.
Calyculin A is a protein phosphatase inhibitor, and Rabbit anti-53BP1 (4937) is an antibody that recognizes the DNA damage response protein 53BP1.
The SpectraMax L luminometer is a device used for quantifying luminescent signals, such as those generated by luciferase reporter assays.
Mimosine is an amino acid that can induce cell cycle arrest at the G1/S transition.
By incorporating these related terms and concepts, researchers can enhance their understanding and optimization of Actinomycin D1 studies, leveraging the power of PubCompare.ai's AI-driven insights to streamline their research workflow and achieve better results.
One typo: 'Actnomycin D1' should be 'Actinomycin D1'.